论文部分内容阅读
目的：研究乳腺癌中Ｂｃｌ－２的表达与激素受体和预后的关系。方法：应用免疫组化法检测７５例乳腺癌中Ｂｃｌ－２、ＥＲ、ＰＲ的表达。结果：５３例（７１％）Ｂｃｌ－２阳性，其中５０例（９４％）ＥＲ阳性，４４例（８３％）ＰＲ阳性，Ｂｃｌ－２的表达与ＥＲ、ＰＲ显著相关（Ｐ均＜０．００５）。Ｂｃｌ－２阳性者五年存活率为８１．１％，阴性者仅为２７．３％，两者有显著性差异（Ｐ＜０．００５）。结论：Ｂｃｌ－２表达与ＥＲ、ＰＲ等诸多临床病理特征相关，可作为激素治疗（内分泌治疗）、化疗或放疗的疗效预测指标。
Objective: To study the relationship between Bcl-2 expression and hormone receptor and prognosis in breast cancer. Methods: Immunohistochemistry was used to detect the expression of Bcl-2, ER and PR in 75 cases of breast cancer. RESULTS: 53 cases (71%) were positive for Bcl-2, of which 50 cases (94%) were positive for ER and 44 cases (83%) were positive for PR. The expression of Bcl-2 was significantly associated with ER and PR (P < 0.005. ). The five-year survival rate of Bcl-2 positive was 81.1%, and the negative was only 27.3%. There was a significant difference between the two (P<0.005). Conclusion: The expression of Bcl-2 is associated with many clinicopathological features such as ER and PR. It can be used as a predictor of the efficacy of hormone therapy (endocrine therapy), chemotherapy or radiotherapy.